Cocrystal Pharma (COCP) EBIT (2010 - 2026)

Cocrystal Pharma has disclosed EBIT across 17 years of filings, most recently posting -$3.2 million for Q2 2026.

• In Q2 2026, EBIT fell 51.04% year-over-year to -$3.2 million; the TTM figure through Jun 2026 stood at -$10.1 million (up 20.53% YoY), while the FY2025 annual figure was -$9.0 million, up 49.55% from the prior year.
• EBIT came in at -$3.2 million for Q2 2026 at Cocrystal Pharma, down from -$2.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$2.1 million in Q3 2025 to a low of -$24.4 million in Q2 2022.
• Average EBIT over 5 years is -$5.0 million, with a median of -$4.3 million recorded in 2022.
• Year-over-year, EBIT slumped 538.14% in 2022 and surged 82.24% in 2023.
• Over 5 years, EBIT stood at -$4.5 million in 2022, then fell by 3.64% to -$4.7 million in 2023, then soared by 30.78% to -$3.2 million in 2024, then advanced by 23.19% to -$2.5 million in 2025, then retreated by 28.34% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$3.2 million in Q2 2026, -$2.4 million in Q1 2026, and -$2.5 million in Q4 2025.